WG
TVRD

Winton Group’s Tvardi Therapeutics TVRD Stock Holding History

Winton Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-564
Closed -$247K – 1177
2021
Q4 		$247K Sell
564
-568
-50% -$285K 0.02% 889
2021
Q3 		$630K Buy
1,132
+499
+79% +$250K 0.04% 742
2021
Q2 		$325K Buy
+633
New +$401K 0.02% 1145
2020
Q4 		– Sell
-639
Closed -$293K – 1544
2020
Q3 		$293K Sell
639
-114
-15% -$66.2K 0.01% 1258
2020
Q2 		$463K Buy
+753
New +$416K 0.01% 1196

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Winton Group's TVRD Position: Q1 2022 in Review

Winton Group sold out of Tvardi Therapeutics (TVRD) in Q1 2022, closing a stake of 564 shares — an estimated $247K sold.

Winton Group first reported a position in TVRD in Q2 2020 and held it in 5 quarters. The position peaked at $630K in Q3 2021. 183 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Winton Group reported no remaining Tvardi Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Winton Group sold 564 Tvardi Therapeutics shares in Q1 2022, an estimated $247K.
  • Winton Group first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 5 quarters.
  • Winton Group's Tvardi Therapeutics position peaked at $630K in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Winton Group's 13F filing for Q1 2022, filed 11 May 2022.